Merck CEO joins hunt for 'lots' of new drug deals

Merck CEO Ken Frazier

While many of its big rivals have been wheeling and dealing over the last few years, Merck has largely been quietly focused on absorbing Schering-Plough into its global system. But now Merck CEO Ken Frazier tells The Wall Street Journal that the Big Pharma giant plans to get busy making targeted deals. Lots of them. "As the CEO of Merck, I see my number one responsibility is to help drive the sustainability of R&D inside the company," he said. "And my hope is that we'll be able to complement what we are doing internally, with targeted deals on the outside to get the best of science, avoiding if we can a big merger and that will be my expectation and my goal." Story (sub. req.)

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.